NAMI Pharma Marketing Blog Grassley
View PDF of blog article here
Similar Posts
Antibiotic Ketek Trial in Children
One day following a rport in The New York Times, Sanifo-Aventis, manufacturer of Ketek, suspended the trial in children. The FDA has not announced any action.
Pfizer Statements RE: Bextra, Celebrex, Neurontin Shown to be Lies
Pfizer Statements RE: Bextra, Celebrex, Neurontin Shown to be Lies Fri, 08 Apr 2005 The New York Times reports that “as recently as Tuesday [Pfizer] assured Wall Street that sales of Celebrex and Bextra would soon rebound. It was the latest in a string of announcements by the company regarding…
FDA Critics Slam Plan for Safety Reform – Nature
FDA Critics Slam Plan for Safety Reform – Nature Thu, 17 Feb 2005 This is smoke and mirrors and musical chairs. Vera Sharav Alliance for Human Research Protection, New York http://www.nature.com/news/2005/050214/full/050214-11.html Published online: 17 February 2005; | doi:10.1038/news050214-11 FDA critics slam plan for safety reform Emma Marris Calls grow for…
Psychiatry’s “Desperate Cures?” Electric Switches for Depression?
An OpEd in The New York Times (below) is trumpeting psychiatry’s latest “cure” for depression: it requires surgical implantation of electrodes in the brain, continued “maintenance” with powerful psychotropic drugs, and it costs $40,000.
US Inspector General Report: Antipsychotic Drug Hazards
An audit by Daniel Levinson, Inspector General of DHHS, confirms what has already been documented: that antipsychotics are widely misprescribed for unapproved uses and taxpayers are saddled with the high cost through Medicaid and Medicare.
FDA Officials Tried to tone Down Report of 27,000 heart attacks on Vioxx – WSJ – WashPost
FDA Officials Tried to tone Down Report of 27,000 heart attacks on Vioxx – WSJ – WashPost Sun, 10 Oct 2004 The FDA attempted to block a senior medical officer from making his findings known about the lethal hazards of Vioxx: Senator Chuck Grassley stated: “Instead of acting as a…